Pieris Pharmaceuticals Inc (PIRS)

HEALTH CARE: PHARMACEUTICALS
SIC: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

255 STATE STREET BOSTON, MA 02109

Pieris Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing therapeutic proteins for oncology, immunological disorders and anemia. The Company's proprietary drug technology, Anticalins, is based on human proteins called lipocalins. Pieris has a pipeline of Anticalin therapeutics.

Data based on most recent fiscal year report
Market Cap172.637 Million Shares Outstanding54.98 Million Avg Volume674.497 Thousand
1-Yr BETA vs S&P TR1.564 Current Ratio2.82 Quick Ratio2.82
View SEC Filings from PIRS instead.

View recent insider trading info

Funds Holding PIRS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PIRS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

AQUILO CAPITAL MANAGEMENT, LLC

  • 10% Owner
5,575,530 2020-03-12 1

KHUONG CHAU QUANG

  • Director
348,473 2020-03-06 0

BARBIER ANN CHIEF MEDICAL OFFICER

  • Officer
0 2020-03-03 1

RICHMAN MICHAEL PRESIDENT & CEO

  • Officer
  • Director
0 2020-02-28 4

YODER STEPHEN S. CHIEF EXECUTIVE OFFICER

0 2020-02-27 1

KAUFMANN HITTO SVP, CHIEF SCIENTIFIC OFFICER

0 2020-02-27 3

BURES THOMAS VICE PRESIDENT, FINANCE

0 2020-02-27 2

SHERMAN MATTHEW L EVP & CHIEF MEDICAL OFFICER

  • Officer
36,760 2020-02-18 1

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
424,419 2020-02-13 2

BIZZARI JEAN-PIERRE

0 2020-01-25 1

KIRITSY CHRISTOPHER P

0 2020-01-25 1

GERAGHTY JAMES A

0 2020-01-25 1

KIENER PETER A

0 2020-01-25 1

SAID MAYA R.

0 2020-01-25 3

PRELACK STEVEN

  • Director
0 2019-06-18 0

MATIS LOUIS CHIEF DEVELOPMENT OFFICER

0 2019-02-26 0

REINE ALLAN CHIEF FINANCIAL OFFICER

0 2019-02-26 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP III LLC

  • 10% Owner
14,915,535 2018-08-16 0

ADAMS JULIAN

  • Director
0 2018-06-26 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP III LLC

ISALY SAMUEL D

  • 10% Owner
5,550,000 2018-01-03 0

DEPTULA-HICKS DARLENE M

  • Director
No longer subject to file 2017-08-09 0

THIBAULT LANCE E ACTING CHIEF FINANCIAL OFFICER

  • Officer
0 2017-02-02 0

KNOPF CLAUDE CHIEF BUSINESS OFFICER

  • Officer
0 2016-11-28 0

TAKKE CHRISTINA

  • Director
0 2015-06-29 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

BURES THOMAS VICE PRESIDENT, FINANCE

2020-02-27 A 80,000 a 80,000 0.00 direct

YODER STEPHEN S. CHIEF EXECUTIVE OFFICER

2020-02-27 A 420,000 a 420,000 0.00 direct

KAUFMANN HITTO SVP, CHIEF SCIENTIFIC OFFICER

2020-02-27 A 45,000 a 45,000 0.00 direct

Elevate your investments